A prospective study of esomeprazole treatment for ulcer healing after gastric endoscopic submucosal dissection

A prospective study of esomeprazole treatment for ulcer healing after gastric endoscopic submucosal dissection - Effect of esomeprazole for post ESD ulcers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010786

Enrollment

200

Registered

2013-05-27

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer

Interventions

Administration of 20mg/day esomeprazole for 2 weeks and 300mg/day rebamipide for 8 weeks Administration of 20mg/day esomeprazole for 4 weeks and 300mg/day rebamipide for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who will undergo ESD for early gastric cancer

Exclusion criteria

Exclusion criteria: age below 20, active gastric or duodenal ulcers, hypersensitivity to esomeprazole or rebamipide, severe heart disease, severe renal dysfunction, severe liver dysfunction, expectant mothers, patients taking NSAIDs, anticoaglant or antiplatelet drugs and so on

Design outcomes

Primary

Measure	Time frame
the healing rates of post-ESD ulcers 29 days after ESD	—

Countries

Japan

Contacts

Public ContactHiroyuki Suto

University of Fukui Hospital Department of Gastroenterology

hrykstu@u-fukui.ac.jp0776-61-8351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026